Dawnzera Injection, Solution
Product Images NDC 71860-103

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Dawnzera (NDC 71860-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ionis Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10_wash Hands.jpg (10 Wash Hands)

An instructional illustration showing two steps for preparation before injection: on the left, a pair of hands being washed with water and soap; on the right, a hand using a gauze pad to clean an injection site marked in green on the skin.*

FDA Label Image

11_injecting.jpg (11 Injecting)

An instructional diagram showing hands removing a clear cap from a DAWNZERA injection pen. The orange needle shield containing the needle is labeled, illustrating preparation for subcutaneous injection of donidalorsen 80 mg/0.8 mL solution by Ionis Pharmaceuticals Inc.*

FDA Label Image

12_ Begin Injection.jpg (12 Begin Injection)

Illustration showing step-by-step instructions for using the DAWNZERA injection pen: a) placing the pen at a 90-degree angle to the skin, b) pushing the pen down until a click is heard, c) holding the pen in place for 10 seconds before removal.*

FDA Label Image

13_finishing Injection_orange Plunger Rod.jpg (13 Finishing Injection Orange Plunger Rod)

An instructional illustration depicting a hand administering a subcutaneous injection using a syringe with an orange plunger rod. Panel a) shows the syringe being pressed down into the skin, while panel b) shows the syringe being lifted away after injection. The image highlights the orange plunger rod inside the syringe during the process.*

FDA Label Image

14_throw Away.jpg (14 Throw Away)

An instructional illustration showing a hand holding a pen-like injection device with an orange tip above a container filled with a gradient red liquid, demonstrating use or handling of the device.*

FDA Label Image

1_autoinjector.jpg (1 Autoinjector)

DAWNZERA 80 mg/0.8 mL injection solution in a prefilled syringe for subcutaneous use. The image shows a clear syringe barrel filled with liquid, a plunger at one end, and an orange protective cap at the needle end. Manufactured by Ionis Pharmaceuticals Inc.*

FDA Label Image

2_autoinjector Parts.jpg (2 Autoinjector Parts)

An instructional diagram of a subcutaneous injection pen showing and labeling key parts: plunger, viewing window, medicine, clear cap, and orange needle shield (contains needle). The illustration highlights the internal and external components of the injection device for medication delivery.*

FDA Label Image

7_out Of The Fridge.jpg (7 Out Of The Fridge)

An instructional illustration showing a refrigerator on the left, an arrow pointing to a box containing a syringe or injection device in the center, and a stopwatch icon on the right indicating to wait 30 minutes. The image suggests removing the injection device from refrigeration and waiting 30 minutes before use.*

FDA Label Image

8_expiry.jpg (8 Expiry)

An instructional diagram showing a device with a window and an expiration date label. The window contains an indicator represented by two colors, with instruction to 'Check' the indicator and the expiration date labeled as 'EXP YYYY/MM.' This image demonstrates checking the status and expiration date of the product before use.*

FDA Label Image

9_injection Site.jpg (9 Injection Site)

An illustration showing recommended subcutaneous injection sites for DAWNZERA (donidalorsen) solution. The diagram highlights injection areas on the human body: stomach and thighs for all users, and the back of the upper arm specifically for healthcare providers or caregivers administering the injection.*

FDA Label Image

Chemical Structure.jpg (Chemical Structure)

Chemical structure diagram depicting the molecular formula of donidalorsen, the active ingredient in DAWNZERA injection, solution. The image shows detailed bond arrangements and molecular groups, including phosphate and sugar moieties, with a variable group represented as R (OCH2CH2OCH3).*

FDA Label Image

Autoinjector Carton (Dawnzera 80mg Carton)

DAWNZERA (donidalorsen) injection 80 mg/0.8 mL is a subcutaneous human prescription drug packaged as a single-dose autoinjector. The label indicates it is for treatment of adult and adolescent patients with HAE. Labeler information is Ionis Pharmaceuticals Inc., with the product NDC 71860-103. The packaging features a white and orange design with a barcode and dosage details.*

FDA Label Image

Autoinjector Label (Dawnzera 80mg Label)

DAWNZERA 80 mg/0.8 mL injection label for subcutaneous use. The label states that each autoinjector contains 80 mg donidalorsen. Distributed by Ionis Pharmaceuticals Inc. It includes storage information to keep refrigerated at 2°C to 8°C, a barcode, and NDC 71860-103-01.*

FDA Label Image

Figure 1.jpg (Figure 1)

A line graph showing the mean investigator-confirmed attack rate over 24 weeks for DAWNZERA 80 mg subcutaneous injections given every 4 weeks and every 8 weeks compared to placebo. The y-axis represents the attack rate in attacks per 4 weeks, and the x-axis represents time in weeks. Both DAWNZERA treatment groups show a decrease in attack rate over time relative to placebo.*

FDA Label Image

Wipe-container-cotton-bandage.jpg (Wipe Container Cotton Bandage)

An instructional illustration showing medical supplies associated with medication administration: a cotton ball or gauze, a sharps container, an alcohol wipe, and a small bandage. Each item is labeled and depicted with simple graphics.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.